PANTHERx® Specialty Pharmacy Selected by Otsuka to Distribute JYNARQUE
Published: May 10, 2018
PITTSBURGH, May 10, 2018 /PRNewswire/ -- PANTHERx® Specialty Pharmacy (PANTHERx®), THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE™ (tolvaptan), the only FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD). PANTHERx® is one of just three pharmacies providing nationwide access to the medication.
ADPKD is one of the most common, life-threatening genetic diseases, diagnosed in 140,000 Americans. In patients with this condition, fluid-filled cysts develop, enlarge in both kidneys, and eventually lead to kidney failure. ADPKD is the fourth leading cause of kidney failure and more than 50 percent of people with this condition will develop kidney failure by age 57.
JYNARQUE™ is a selective vasopressin V2-receptor antagonist. This means it blocks vasopressin, an anti-diuretic hormone secreted by the pituitary gland, which plays a key role in the fluid balance of the kidneys. By blocking this hormone, the drug can decrease cyst-cell proliferation and fluid secretion, which ultimately can reduce cyst growth. JYNARQUE™ was shown to reduce the rate of kidney function decline by 35 percent over a 12-month period when compared to a placebo, in patients with ADPKD.
"We are delighted to offer JYNARQUE™ as a breakthrough treatment to patients impacted by ADPKD, a rare and devastating condition" said Dr. Gordon Vanscoy, Chairman and CEO at PANTHERx®. "With our award-winning focus on patient satisfaction, PANTHERx®'s RareCareTM teams work diligently to ensure our patients receive innovative therapy solutions while providing the highest-touch care possible."
For more information about RareCareTM services for patients with ADPKD, contact us at 833-599-2245 or email ADPKDRareCare@pantherspecialty.com
About PANTHERx® Specialty Pharmacy
PANTHERx® Specialty Pharmacy, THE Rare Disease Specialty Pharmacy®, is quad-accredited and a back-to-back Zitter Health Insights Patient Choice Award winner headquartered in Pittsburgh, Pennsylvania. PANTHERx® Specialty's mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. PANTHERx® works daily to Reinvent Specialty, Revolutionize Pharmacy, and Redefine Care®, by developing focused solutions, bold innovations, and novel clinical services associated with life-transforming therapies.
Robert Snyder, VP Strategic Partnerships
View original content with multimedia: http://www.prnewswire.com/news-releases/pantherx-specialty-pharmacy-selected-by-otsuka-to-distribute-jynarque-300645402.html
SOURCE PANTHERx Specialty Pharmacy